The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
March 14th 2024
Results showed the cell-free DNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions.
Show Me the Data! Navigating FGFR, FGFR Resistance, Immunotherapy, and a World of Clinical Trials in Cholangiocarcinoma Treatment
View More
Expert Illustrations & Commentaries™: A Closer Look at Emerging Therapies in IBS-C
View More
4th Annual Live Medical Crossfire® IBS and IBD
View More
Advances In™ KRAS Inhibition: Modern Considerations In Targeting KRAS-Mutated Lung, Colorectal, And Pancreatic Cancers
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
April 17, 2024
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Rapid Oncology Abstract Review®: Key Updates in Gastrointestinal Cancers from the ASCO Annual Meeting
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
Medical Crossfire®: Bridging Precision Medicine Techniques and Emerging Treatments in Metastatic Colorectal Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Burst CME: Incorporating the Latest Updates in IBS Treatment into Your Practice
View More
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Oncology Town Hall: Live Report from Barcelona for Advances in the Treatment of GI Cancers
View More
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 20th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Working Group: Streamlining the Pathway from Diagnosis to Treatment in Inflammatory Bowel Disease
View More
Advances In™: The Evolving Role of VEGFR in the Treatment of Refractory mCRC
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Shared Decision-Making, Routine Monitoring Among Best Practices for Managing EoE
February 5th 2024The literature review discusses the rising incidence of eosinophilic esophagitis, highlighting the efficacy of proton pump inhibitors, challenges in diagnosis, and the need for collaborative decision-making in its management.
Long Time Coming: Pediatric Gastroenterologists React to New Dupilumab EoE Approval
February 1st 2024Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.
Dupilumab's Role in Managing Pediatric EoE, with Evan Dellon, MD, MPH
January 25th 2024We sat down with Evan Dellon, MD, MPH, to discuss the use of dupilumab in pediatric EoE patients, with the agent gaining FDA approval as the first and only indication for this patient population on January 25, 2024.
Safety, Efficacy of Tacrolimus for Ulcerative Colitis Not Impacted by Age
January 16th 2024Patients ≥ 65 years of age experienced similar rates of remission and adverse events compared to their younger counterparts, with no significant difference in change in renal function observed between the 2 groups.
Omadacycline Shows Promise as Safe, Effective C Diff Antibiotic Compared to Vancomycin
January 8th 2024Participants given omadacycline had high fecal concentrations with a distinct microbiome profile compared to those in the vancomycin group, with study results calling attention to the importance of antibiotics’ impact on the gut microbiome.
Vonoprazan for the Treatment of Erosive Esophagitis: A Randomized Controlled Trial
December 6th 2023While more studies are needed to ensure the safety of long-term therapy with PCABs, this study establishes a role for the use of vonoprazan in the healing and maintenance of healing in patients with erosive esophagitis.